SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, Jackson E, Kelcz F, Yeh BM, Lee FT Jr, Charnsangavej C, Park JW, Ashton EA, Steinfeldt HM, Pithavala YK, Reich SD, Herbst RS. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 2005; 23: 54645473.
  • 2
    Mross K, Drevs J, Muller M, Medinger M, Marme D, Hennig J, Morgan B, Lebwohl D, Masson E, Ho YY, Gunther C, Laurent D, Unger C. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumors. Eur J Cancer 2005; 41: 12911299.
  • 3
    Thomas AL, Morgan B, Horsfield MA, Higginson A, Kay A, Lee L, Masson E, Puccio-Pick M, Laurent D, Steward WP. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 2005; 23: 41624171.
  • 4
    Padhani AR. MRI for assessing antivascular cancer treatments. Br J Radiol 2003; 76: 6080.
  • 5
    Padhani AR, Leach MO. Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging. Abdom Imaging 2005; 30: 324341.
  • 6
    Ichikawa T, Arbab AS, Araki T, Touyama K, Haradome H, Hachiya J, Yamaguchi M, Kumagai H, Aoki S. Perfusion MR Imaging with a superparamagnetic iron oxide using T2-weighted and susceptibility-sensitive echoplanar sequences: evaluation of tumor vascularity in hepatocellular carcinoma. AJR 1999; 173: 207213.
  • 7
    Park YN, Kim Y-B, Yang KM, Park C. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch Pathol Lab Med 2000; 124: 10611065.
  • 8
    Padhani AR. Dynamic contrast-enhanced MRI in clinical oncology. Current status and future directions. J Magn Reson Imaging 2002; 16: 407422.
  • 9
    Galbraith SM, Lodge MA, Taylor NJ, Rustin GJS, Bentzen S, Stirling JJ, Padhani AR. Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumors: comparison of quantitative and semi-quantitative analysis. NMR Biomed 2002; 15: 132142.
  • 10
    Dale BM, Jesberger JA, Lewin JS, Hillenbrand CM, Duerk JL. Determining and optimizing the precision of quantitative measurements of perfusion from dynamic contrast enhanced MRI. J Magn Reson Imaging 2003; 18: 575584.
  • 11
    Ahearn TS, Staff RT, Redpath TW, Semple SI. The effects of renal variation upon measurements of perfusion and leakage volume in breast tumors. Phys Med Biol 2005; 49: 20412051.
  • 12
    Asbach P, Klessen C, Hein1 PA, Stemmer A, Hamm B, Taupitz M. Respiratory triggered diffusion weighted MR imaging of the liver. Proc Int Soc Magn Reson Med 2006; 14: 3313.
  • 13
    Griswold MA, Jakob PM, Heidemann RM, Nittka M, Jellus V, Wang J, Kiefer B, Haase A. Generalized autocalibrating partially parallel acquisitions (GRAPPA). Magn Reson Med 2002; 47: 12021210.
  • 14
    Huang F, Akao J, Vijayakumar S, Duensing GR, Limkeman M. K-t GRAPPA: a k-space implementation for dynamic MRI with high reduction factor. Magn Reson Med 2005; 54: 11721184.
  • 15
    Li K-L, Zhu XP, Waterton J, Jackson A. Improved 3D quantitative mapping of blood volume and endothelial permeability in brain tumors. J Magn Reson Imaging 2000; 12: 347357.
  • 16
    Golder ER, Settle JG. The Box-Muller method for generating pseudo-random normal deviates. Appl Stat 1976; 25: 1220.
  • 17
    Bazelaire C, Rofsky NM, Duhamel G, Zhang J, Michaelson MD, George D, Alsop DC. Combined T2* and T1 measurements for improved perfusion and permeability studies in high field using dynamic contrast enhancement. Eur Radiol 2006; 16: 20832091.
  • 18
    Roberts C, Issa B, Stone A, Jackson A, Waterton JC, Parker GJM. Comparative study into the robustness of compartmental modeling and model-free analysis in DCE-MRI studies. J Magn Reson Imaging 2006; 23: 554563.
  • 19
    Mathew RJ, Wilson WH. Caffeine induced changes in cerebral circulation. Stroke 1985; 16: 814817.
  • 20
    Lunt MJ, Ragab S, Birch AA, Schley D, Jenkinson DF. Comparison of caffeine-induced changes in cerebral blood flow and middle cerebral artery blood velocity shows that caffeine reduces middle cerebral artery diameter. Physiol Meas 2004; 25: 467474.
  • 21
    McCusker RR, Goldberger BA, Cone EJ. Caffeine content of specialty coffees. J Anal Toxicol 2003; 27: 520522.
  • 22
    Physician's drug handbook. Philadelphia: Lippincott Williams & Wilkins, 2003.
  • 23
    Shyu JK, Wang YJ, Lee SD, Lu RH, Lo KJ. Caffeine clearance test: a quantitative liver function assessment in patients with liver cirrhosis. Zhonghua Yi Xue Za Zhi (Taipei) 1996; 57: 329334.
  • 24
    Rojo De Camargo MC, Toledo MCF. HPLC determination of caffeine in tea, chocolate products and carbonated beverages. J Sci Food Agric 1999; 79: 18611864.
  • 25
    Caron MF, Song J, Ammar R, Kluger J, White CM. An evaluation of the change in electrocardiographic P-wave variables after acute caffeine ingestion in normal volunteers. J Clin Pharm Ther 2001; 26: 145148.
  • 26
    Ammar R, Song JC, Kluger J, White CM. Evaluation of electrocardiographic and hemodynamic effects of caffeine with acute dosing in healthy volunteers. Pharmacotherapy 2001; 21: 437442.